INTERPHEX 2013: Aligning with Industry's Needs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

INTERPHEX 2013: Aligning with Industry's Needs

Pharmaceutical Technology
Volume 37, Issue 4, pp. 12


Russ Somma
The pharmaceutical industry continues to move ahead with its trajectory being tweaked by various outside forces. The highly regulated nature of our industry is a major contributor, while the need to do more with less continues to vex our everyday efforts. These factors are acutely realized when we congregate with fellow industry professionals at society and professional meetings. I use these interactions to explore the next big need for my clients as well as to craft a strategy that will help address these needs. INTERPHEX 2013, while being a continuation of the journey described by Bob Stewart last year, is also a realization of this “group thinking” fueled by current needs and pressures of our industry. It takes only a quick glance at the conference agenda and list of exhibitors to fully appreciate this synergy.

The customized conference content of INTERPHEX 2013 is the product of group thinking carried out in a structured environment, which we refer to glibly as the advisory board. When you ask 15 industry professionals (the board) from across all sectors of our industry, you are guaranteed of getting valued input as well as things that are current and need to be addressed. The five conference tracks—regulatory quality assurance/quality control, product development, facility and process design, manufacturing and packaging, and supply chain—were pressure tested at INTERPHEX 2012 and have been leveraged effectively here for INTERPHEX 2013. Current Development Best Practices for IR and MR Dosage Forms will be discussed by Glenn Van Buskirk and will touch upon aspects of the current effort to address the needed updates for FDA guidance in the area of post-approval changes. The industry has regularly used the Scale-Up and Post-Approval Change (SUPAC) guidances that were issued more than a decade ago. The widespread use of these guidances along with current industry need has brought about a rethinking in this area and will produce a work product that will be a reliable and time-proven asset.

A keynote address, Reorganizing for the Future: Succeeding in the New Pharmaceutical Industry, will be given by Rajesh Nair from his perspective as president of Indegene. With a track record of having worked and consulted for many firms, Indegene has assisted various companies as they navigate through strategies to become more agile as they bring products to market and leverage existing product lines through a successful lifecycle.

A team from Duquesne University lead by Jim Drennen and Benoit Inge has assembled a must-see session that will take the attendee through a practical utilization of aspects of quality by design as well as the application of key process control tools such as PAT. This will be followed by a panel discussion lead by Carl Anderson, also from Duquesne University. The panel will be case study-driven with experts from regulatory, development, quality, and the consulting sectors. The panelists will share their views as well as address must-have answers from attendees.

Combination products along with information-rich case studies will be presented from leading medical device manufacturers. David Armbruster from DePuy Synthes and Roy Fennimore from Johnson & Johnson will walk the attendees through each of their sessions. David will discuss the aspects of product realization from concept through manufacture while Roy will detail technology transfer for design control of convergent products.

A high priority has been placed on the “meeting place” that allows professionals to gather and exchange ideas. As highlighted by Bob Stewart, “there is a need to connect, face-to-face, in order to teach, to learn, to do business and to know each other better. Personal collaboration is critical to the industry INTERPHEX serves, and collaboration can begin with a conversation, with a meeting.” INTERPHEX has established just such a meeting place and forum.

The INTERPHEX team looks forward to meeting you at the Javits Center in New York City on April 23–25, 2103. Let us know your thoughts, at any time. We intend to serve the industry and continue our mission to make INTERPHEX the venue to learn it, hear it, see it, touch it, and procure it.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here